SCHEMBL26239368

SCHEMBL26239368

CC(=O)c1cc(C)nc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
NPC1 O15118 3/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 4/20 0.40
HPGD P15428 2/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA5A P35218 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
POLB P06746 1/20 0.37
HSD17B10 Q99714 1/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
SYK P43405 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30989545 0.88 CA5A (0.43) HSP90AA1HSP90AB1ALDH1A1MEN1KMT2A
SCHEMBL17858833 0.85 HSP90AA1 (0.47) HSP90AA1HSP90AB1NPC1RAB9AALDH1A1
SCHEMBL27250198 0.81 HSP90AA1 (0.43) HSP90AA1HSP90AB1NPC1ALDH1A1HPGD
SCHEMBL23411999 0.80 GPBAR1 (0.44) HSP90AA1HSP90AB1HPGDMAPTCA5A
SCHEMBL29723389 0.80 GPBAR1 (0.44) HSP90AA1HSP90AB1HPGDMAPTCA5A
SCHEMBL5762468 0.80 NPC1 (0.50) NPC1RAB9AALDH1A1HPGDMAPT
SCHEMBL26919214 0.79 ALOX15 (0.47) ALDH1A1MAPTCA5AL3MBTL1POLB
SCHEMBL16406338 0.76 HSP90AA1 (0.46) HSP90AA1HSP90AB1NPC1ALDH1A1HPGD
SCHEMBL21212120 0.76 HPGD (0.51) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL26918823 0.75 KDM4E (0.42) ALDH1A1HPGDMAPTL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118974038-A Heterocyclic compounds and methods of use 薛定谔公司 2024-11-15 CN disclosed
US-20230348424-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHRÖDINGER, INC. 2023-11-02 US disclosed
US-20230348424-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHRÖDINGER, INC. 2023-11-02 US disclosed
WO-2023150291-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHRÖDINGER, INC. (US) 2023-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348424-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE APC, RCC2, CDC37 HSP90AA1 392/4885HSP90AB1 351/4885NPC1 590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.